PeptideStack
5.2kquestions
20kanswers
220users

Does aggregation dominate for a GLP-1 receptor agonist held at 4 °C?

Asked 12 Sept 2024Modified 19 months agoViewed 31k times
40

Setup, so nobody has to ask: aggregation · a GLP-1 receptor agonist · 4 °C.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

Why does this happen, and what would falsify the usual explanation?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
shareeditfollowflag
RS
askedruaidhri_o_shea25k2712 Sept 2024
Is there a printed date on the vial, and do you know what it was derived from? – nine_point_nine 3 months ago
8Voting to keep this open — it is more specific than it first looks. – ayo_fadipe 31 days ago
add a comment

5 Answers

Sorted by votes
77

At 4 °C the question is which route is fastest, not whether aggregation happens — and the routes do not share an activation energy, so their ranking changes with temperature. 4 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. That multiplier is an average over every route at once, which is exactly why it cannot tell you which one wins. Molecules associate without any covalent change, so the mass is unchanged and a reversed-phase run — which is performed in organic solvent — mostly dissolves the evidence before it can be measured. So the way to answer it for your vial is to pick the method that sees aggregation specifically and run it against a control held cold, rather than to infer a mechanism from a purity number that averages all of them.

The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

It helps to be literal here: deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
DB
answeredDr_Signe_Baldursdottir29k2722 Dec 2024
3Same experience here, different supplier. – Dr_Elias_Weiss 14 days ago
2I would add a sentence about light, since tryptophan-containing sequences care. – yuki_morishita 9 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
50

Answering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

Sequence decides which pathways are even available. Check the residues.

edited 5 Jan 2025 by bufferline42 — tightened the wording; no substantive change

shareimprove this answerflag
BU
answeredbufferline4230k1382 Jan 2025
Worth adding that residual moisture predicts this better than any printed date. – Dr_Rosalind_Achebe 4 months ago
add a comment
40

More usefully, asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

It helps to be literal here: hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

shareimprove this answerflag
HN
answeredhalvard_ness69k4715 Sept 2024
8This should be linked from the help pages. – Dr_Colm_Fitzhenry 8 months ago
7The desiccant point is under-appreciated and costs nothing to act on. – bac_or_bust 6 months ago
add a comment
32

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

Cold, dry, dark, still. Those four words cover most of the mitigation.

shareimprove this answerflag
M4
answeredmz_4113101k35826 Sept 2024
24

This is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

Sequence determines which pathways apply, so general statements are general.

At dilute concentrations, suspect adsorption before you suspect chemistry.

shareimprove this answerflag
RC
answeredRP_C18105k3487 Oct 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.